Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors
Authors:
- Kyoko TominagaKTKyoko Tominaga
Open Access
Abstract
BACKGROUND: Several studies have shown that lysophosphatidic acid (LPA), a phospholipidic chemical mediator, is relevant to the pathogenesis of ovarian carcinoma. Higher plasma levels of LPA have been reported in patients with ovarian carcinoma than in healthy patients, and LPA is known to activate ovarian carcinoma cells. To determine the reason for the increased plasma LPA levels in ovarian carcinoma patients, we compared the activities of serum lysophospholipase D, a novel LPA‐producing metallo‐enzyme, in healthy volunteers, patients with benign ovarian tumor, and patients with ovarian carcinoma.METHODS: Lysophospholipase D activity was assessed by measuring the percentage conversion of [14C]palmitoyl‐lysophosphatidylcholine (LPC) added to human serum. The apparent enzyme activities were corrected based on the serum levels of palmitoyl‐LPC determined by gas‐liquid chromatography after its purification and conversion to fatty acid methyl esters.RESULTS: The apparent activity of lysophospholipase D in serum preparations from four patients with ovarian carcinoma at Stage IV was significantly higher than those from five healthy subjects, five patients with benign ovarian tumors, and fourteen patients with ovarian carcinoma at Stages I (n = 5), II (n = 4), and III (n = 5). The serum levels of LPC, an endogenous substrate of lysophospholipase D, in ovarian carcinoma patients were less than those in patients with benign ovarian tumors. There were no significant differences in the corrected lysophospholipase D activity for the LPC levels in healthy women, patients with benign ovarian tumors, and patients with ovarian carcinoma at various stages.CONCLUSIONS: The current results suggest that lysophospholipase D is not associated with the elevated plasma levels of LPA in ovarian carcinoma patients previously reported, although only a limited number of patients were analyzed. Cancer 2002;94:141–51. © 2002 American Cancer Society.Keywords
This publication has 32 references indexed in Scilit:
- Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1‐phosphateThe FASEB Journal, 1998
- Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic CancersJAMA, 1998
- Malignant effusions contain lysophosphatidic acid (LPA)-like activityAnnals of Oncology, 1998
- Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex.Journal of Cell Biology, 1996
- Lysophospholipids activate ovarian and breast cancer cellsBiochemical Journal, 1995
- A family of phospholipid autacoids: Occurrence, metabolism and bioactionsProgress in Lipid Research, 1995
- A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumoursBritish Journal of Cancer, 1991
- Lysophosphatidate-induced cell proliferation: Identification and dissection of signaling pathways mediated by G proteinsCell, 1989
- Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal speciesLipids, 1978
- Pharmacologically active acidic phospholipids and glycolipidsBiochemical Pharmacology, 1963